Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation

Basic Research in Cardiology

Volumn 94, Issue 2, 1999, Pages 128-135

  Su, J ^a   Barbe, F ^a   Houel R ^a   Guyene, T T ^b   Crozatier, B ^a   Hittinger, L ^a  

^a INSERM   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin II receptor antagonist; Congestive heart failure; Conscious dog; Vascular tone

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTERIAL PRESSURE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE PRESSURE; HEART OUTPUT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TACHYCARDIA; VASCULAR RESISTANCE; VASODILATATION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DOGS; ENALAPRILAT; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; IMIDAZOLES; MALE; RECEPTORS, ANGIOTENSIN; RENIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VASODILATION;

EID: 0032932278     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003950050135     Document Type: Article

References (36)

1. Barbe F, Su JB, Guyenne TT, Crozatier B, Menard J, Hittinger L (1996) Bradykinin pathway is involved in the acute hemodynamic effects of enalaprilat in conscious dog with heart failure. Am J Physiol 270 (Heart Circ Physiol 39): H1985-H1992
2. Brown JJ, Davies DL, Johnson VW, Lever AF, Robertson JIS (1970) Renin relationships in congestive cardiac failure, treated and untreated. Am Heart J 80: 329-342
3. Cascieri D, Bull HG, Mumford RA, Patchett AA, Thornberry NA, Liang T (1984) Carbooxyl-terminal tripepetidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potensiation of substance P activity in vivo by captopril and MK-432. Mol Pharmacol 10: 13-23
4. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Markris L, Rucinska E (1995) Losartan in heart failure hemodynamic effects and tolerability. Circulation 91: 691-697
5. Curtiss C, Cohn JN, Vrobel T, Franciosa JA (1978) Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 58: 763-770
6. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH (1981) Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63: 645-651
7. Fitzpatrick MA, Rademaker MT, Charles C J, Yandle TG, Espiner EA, Ikram H (1992) Angiotensin II receptor antagonism in ovine heart failure: acute hemodynamic, hormonal, and renal effects. Am J Physiol 263: H250-H256
8. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicolas J, Liang C-S, Kubo SH, Rudin-Toretsky E, Yusuf S, for the SOLVD investigators (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 82: 1724-1729
9. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, Dekock M (1993) Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88: 1602-1609
10. Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, Weitz D, Bohn DL, Wenger HC, Vassil TC, Stone CA (1981) Effect of N-((S)-1-Carboxy-3-Phenylpropyl)-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther 216: 552-557
11. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ (1991) Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 69: 475-482
12. Hübner R, Högemann AM, Sunzel M, Riddell JG (1997) Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypert 11 (Suppl 2): s19-s25
13. Isaacson JS, Reid IA (1990) Importance of endogenous angiotensin II in the cardiovascular responses to sympathetic stimulation in conscious rabbits. Circ Res 66: 662-671
14. Kubo SH, Clark M, Laragh JH, Borer JS, Cody RJ (1987) Identification of neurohormonal activity in mild congestive heart failure. Am J Cardiol 60: 1322-1328
15. Lenfant C (1994) Report of the task force on research in heart failure. Circulation 90: 1118-1123
16. Kumagai K, Reid IA (1994) Losartan inhibits sympathetic and cardiovascular responses to carotid occlusion. 23 (part 2): 827-831
17. Liu Y-H, Yang X-P, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA (1997) Effects of angiotensin-converting enzyme inhibitors and angiotensin II Type 1 receptor antagonists in rats with heart failure. J Clin Invest 99: 1926-1935
18. Margulies KB, Perrella MA, McKinley LJ, Burnett JC Jr (1991) Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 88: 1636-1642
19. Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, Murasawa S, Kizima K, Muruyama K, Horiuchi M, Dzau VJ, Takahashi H, Iwasaka, Tinada M, Matsubara H (1998) Cardiac specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 101: 527-535
20. McDonald KM, Garr M, Carlyle PF, Francis GS, Hauer K, Hunter DW, Parish T, Stillman A, Cohn JN (1994) Relative effects of α-adrenoceptor blockade converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation 90: 3034-3046
21. McDonald KM, Mock J, D'Alola A, Hauer K, Francis GS, Parish T, Stillman A, Cohn JN (1995) Bradykinin antagonism inhibits the antigrowth effects of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 91: 2043-2048
22. Merrill AJ, Morrison JL, Brannon ES (1946) Concentration of renin in renal venous blood in patients with chronic heart failure. Am J Med 1: 468-72
23. Murakami M, Suzuki H, Naitoh M, Matsumoto A, Kageyama Y, Tsujimoto G, Saruta T (1995) Blockade of the renin-angiotensin system in heart failure in conscious dogs. J Hypert 13: 1405-1412
24. Raya TE, Fonken SJ, Lee RW, Daugherty S, Goldman S, Wong PC, Timmermans PBMWM, Morkin E (1991) Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens 4: 334S-340S
25. Richard V, Berdeaux A, Giudicelli JF (1993) Systemic and coronary effect of the angiotensin II receptor antagonist EXP 3174 in dogs. J Cardiovasc Pharmacol 22: 52-57
26. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H (1994) Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infraction in the rat. Circulation 89: 2273-2282
27. Seyedi N, Xu XB, Nasjletti A, Hinzte TH (1995) Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 26: 164-170
28. Spinale F, de Gasparo M, Whitebread S, Hebbar L, Clair M, Melton M, Krombach S, Mukherjee R, Iannini JOS (1997) Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I. Effects on left ventricular performance and neurohormonal systems. Circulation 96: 2385-2396
29. Spinale F, Mukherjee R, Iannini JP, Whitebread S, Hebbar L, Clair M, Melton M, Cox MH, Thomas PB, de Gasparo M (1997) Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. II. Effects on myocyte contractile processes. Circulation 96: 2397-2406
30. Su JB, Renaud N, Carayon A, Crozatier B, Hittinger L (1994) Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure. Br J Pharmacol 113: 395-402
31. The CONSENSUS trial study group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316: 1429-35
32. The SOLVD investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302
33. Wiemer G, Schölkens BA, Buss R, Wagner A, Heitsch H, Linz W (1993) The functional role of angiotensin II-subtype AT2 receptors in endothelial cells and isolated rat hearts. Pharm Pharmacol Lett 3: 24-27
34. Wong PC, Hart SD, Duncia JV, Timmermans PBMWM (1991) Nonpeptide angiotensin II receptor antagonist. Studies with DuP 753 and EXP 3174 in dogs. Eur J Pharmacol 202: 323-330
35. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252: 719-725
36. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM (1990) Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 255: 211-217